BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25120814)

  • 1. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
    Wang X; Wang G; Hao Y; Xu Y; Zhang L
    Int J Clin Exp Pathol; 2014; 7(7):4310-6. PubMed ID: 25120814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
    Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
    J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
    Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
    Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
    Kato Y; Peled N; Wynes MW; Yoshida K; Pardo M; Mascaux C; Ohira T; Tsuboi M; Matsubayashi J; Nagao T; Ikeda N; Hirsch FR
    J Thorac Oncol; 2010 Oct; 5(10):1551-8. PubMed ID: 20697298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
    Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
    Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
    Kim CH; Kim SH; Park SY; Yoo J; Kim SK; Kim HK
    Cancer Res Treat; 2015 Oct; 47(4):653-60. PubMed ID: 25687872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma.
    Hasanovic A; Ang D; Moreira AL; Zakowski MF
    Lung Cancer; 2012 Aug; 77(2):299-305. PubMed ID: 22542171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
    Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
    Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of epidermal growth factor receptor mutation specific antibodies in lung adenocarcinoma: evaluation of sensitivity, specificity and relationship to histologic subtypes].
    Lai YM; Feng Q; Sun Y; Wang P; Shi YF; Zhao M; Wu Q; Li XH
    Zhonghua Bing Li Xue Za Zhi; 2016 Sep; 45(9):606-11. PubMed ID: 27646888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of EGFR gene mutations in 100 non-small cell lung cancer clinical samples by a real-time polymerase chain reaction method using amplification refractory mutation system specific primers and Taqman fluorescence probes].
    Zhao J; Zhao J; Zhao X; Chen W; Zhong W; Zhang L; Li L; Wang M
    Zhongguo Fei Ai Za Zhi; 2013 Jan; 16(1):25-32. PubMed ID: 23327870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
    Kawahara A; Yamamoto C; Nakashima K; Azuma K; Hattori S; Kashihara M; Aizawa H; Basaki Y; Kuwano M; Kage M; Mitsudomi T; Ono M
    Clin Cancer Res; 2010 Jun; 16(12):3163-70. PubMed ID: 20423982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal Growth Factor Receptor Gene Mutation Detection in Histology and Cytology Specimens of Primary Lung Adenocarcinoma: Immunohistochemistry Versus the Molecular Method.
    Abdul Hamid NS; Mat Zin AA
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1935-1942. PubMed ID: 34181354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer.
    Houang M; Sioson L; Clarkson A; Watson N; Farzin M; Toon CW; Raut A; O'Toole SA; Cooper WA; Pavlakis N; Mead S; Chou A; Gill AJ
    Pathology; 2014 Oct; 46(6):501-8. PubMed ID: 25158821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.
    Wu SG; Chang YL; Lin JW; Wu CT; Chen HY; Tsai MF; Lee YC; Yu CJ; Shih JY
    PLoS One; 2011; 6(8):e23303. PubMed ID: 21858063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study.
    Jain D; Iqbal S; Walia R; Malik P; Cyriac S; Mathur SR; Sharma MC; Madan K; Mohan A; Bhalla A; Pathy S; Kumar L; Guleria R
    Indian J Med Res; 2016 Mar; 143(3):308-14. PubMed ID: 27241644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.
    Mraihi Z; Ben Amar J; Bouacha H; Rammeh S; Hila L
    BMC Pulm Med; 2018 Aug; 18(1):132. PubMed ID: 30092812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.
    Simonetti S; Molina MA; Queralt C; de Aguirre I; Mayo C; Bertran-Alamillo J; Sanchez JJ; Gonzalez-Larriba JL; Jimenez U; Isla D; Moran T; Viteri S; Camps C; Garcia-Campelo R; Massuti B; Benlloch S; Ramon y Cajal S; Taron M; Rosell R
    J Transl Med; 2010 Dec; 8():135. PubMed ID: 21167064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
    Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
    Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.
    Ling Y; Yang X; Li W; Li Z; Yang L; Qiu T; Guo L; Dong L; Li L; Ying J; Lin D
    Oncotarget; 2016 Aug; 7(33):52862-52869. PubMed ID: 27418143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer.
    Jiang G; Fan C; Zhang X; Dong Q; Wang L; Liu Y; Dai S; Yang L; Zhang Y; Yu J; Wang E
    PLoS One; 2013; 8(3):e59183. PubMed ID: 23536868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.